[The role of adipokines in formation of lipid and carbohydrate metabolic disorders in patients with cardiovascular disease]
- PMID: 23293229
[The role of adipokines in formation of lipid and carbohydrate metabolic disorders in patients with cardiovascular disease]
Abstract
Cardio-vascular disease is an important public health problem in all developed countries.The challenge isto learn thepathogenic mechanisms of this disease.Attention of scientists of the world are drown to the role of hormones in the development of adipose tissue metabolic disorders. Adipose tissue is composed of adipocytes embedded in a loose connective tissue meshwork containing adipocyte precursors, fibroblasts, immune cells, and various other cell types. Adipose tissue was traditionally considered an energy storage depot with few interesting attributes. Due to the dramatic rise in obesity and its metabolic sequelae during the past decades, adipose tissue gained tremendous scientific interest. It is now regarded as an active endocrine organ that, in addition to regulating fat mass and nutrient homeostasis, releases a large number of bioactive mediators (adipokines) modulating hemostasis, blood pressure, lipid and glucose metabolism, inflammation, and atherosclerosis. The aim of our study was to examine the metabolic disorders in patients with cardiovascular disease. Based on identifying the nature of changes of insulin antagonists and of insulin sensitizers. We were investigated 68 patients with hypertension, which included 35 women and 33 men.Estimated distance of carbohydrate and lipid metabolism and adipose tissue hormone imbalance. Our results suggest that the mechanisms underlying the progression of diabetes and obesity in patients with hypertension against metabolic disorders that manifest dysfunction of carbohydrate and lipid metabolism are associated with insulinorezistense and hypervisfatinemia and hyperrezistinemia against hypoadiponektinemia occur in hypertensive patients by having diabetes mellitus type 2.
Similar articles
-
Adipose tissue dysfunction in obesity.Exp Clin Endocrinol Diabetes. 2009 Jun;117(6):241-50. doi: 10.1055/s-0029-1192044. Epub 2009 Apr 8. Exp Clin Endocrinol Diabetes. 2009. PMID: 19358089 Review.
-
[Fat mass expansion, fatty acids and adipokines: metabolic markers and risk factors for cardiovascular pathologies].Ann Pharm Fr. 2013 Jan;71(1):13-26. doi: 10.1016/j.pharma.2012.07.008. Epub 2012 Aug 28. Ann Pharm Fr. 2013. PMID: 23348852 Review. French.
-
Visfatin is associated with lipid metabolic abnormalities in Lyon hypertensive rats.Clin Exp Pharmacol Physiol. 2010 Sep;37(9):894-9. doi: 10.1111/j.1440-1681.2010.05402.x. Epub 2010 Apr 26. Clin Exp Pharmacol Physiol. 2010. PMID: 20456420
-
Type 2 diabetes and cardiovascular disease: getting to the fat of the matter.Can J Physiol Pharmacol. 2007 Jan;85(1):113-32. doi: 10.1139/y06-092. Can J Physiol Pharmacol. 2007. PMID: 17487251 Review.
-
Advances in adipokines.Metabolism. 2012 Dec;61(12):1659-65. doi: 10.1016/j.metabol.2012.09.001. Epub 2012 Sep 26. Metabolism. 2012. PMID: 23021039 Review. No abstract available.
Cited by
-
Insulin resistance and its correlation with chemerin and visfatin in Saudi patients with hyperthyroidism.Int J Health Sci (Qassim). 2019 Sep-Oct;13(5):18-21. Int J Health Sci (Qassim). 2019. PMID: 31501648 Free PMC article.
-
Common medicinal plants with antiobesity potential: A special emphasis on fenugreek.Anc Sci Life. 2015 Jul-Sep;35(1):58-63. doi: 10.4103/0257-7941.165629. Anc Sci Life. 2015. PMID: 26600669 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous